Fig. 2From: Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s diseaseTheoretical rate of decline with DMTs. Model showing the theoretical rates of decline with disease-modifying treatment and without. There is an increasing drug–placebo difference over time with cumulative benefit of long-term therapy. Adapted from Cummings & Zhong [81]Back to article page